News Releases
November 5, 2019
Urovant Sciences Reports 2019 Second Fiscal Quarter Financial Results
Additional Formats
October 31, 2019
Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma’s Transaction with Roivant Sciences
Additional Formats
October 29, 2019
Urovant Sciences to Report 2019 Second Fiscal Quarter Financial Results
Additional Formats
October 21, 2019
Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
Additional Formats
September 24, 2019
Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Additional Formats
September 6, 2019
Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
Additional Formats
August 13, 2019
Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results
Additional Formats
August 6, 2019
Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results
Additional Formats
June 13, 2019
Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
Additional Formats
June 6, 2019
Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
Additional Formats
Pagination
Displaying 1 - 10 of 25